It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
8h
Hosted on MSNGLP-1 Drugs and Colonoscopy; GI Symptoms Post-COVID; Identifying High-Risk Barrett'sA systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
2d
News Nation on MSNStudy finds rare vision issues in taking GLP-1 weight loss drugsAlthough reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results